Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance

BACKGROUND & AIMS: The high costs of direct-acting antiviral (DAA) agents to treat chronic hepatitis C virus (HCV) infection have resulted in denials of treatment, but it is not clear whether patients’ access to these therapies differs with their type of insurance. METHODS: We conducted a prospe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Gastroenterol Hepatol
Hlavní autoři: Re, Vincent Lo, Gowda, Charitha, Urick, Paul N., Halladay, Joshua T., Binkley, Amanda, Carbonari, Dena M., Battista, Kathryn, Peleckis, Cassandra, Gilmore, Jody, Roy, Jason A., Doshi, Jalpa A., Reese, Peter P., Reddy, K. Rajender, Kostman, Jay R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4912853/
https://ncbi.nlm.nih.gov/pubmed/27062903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2016.03.040
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky